Vademecum.es6d
La Agencia Europea de Medicamentos acepta revisar la solicitud de GSK de ampliar el uso de Nucala (mepolizumab) para el tratamiento de la EPOC
GSK ha anunciado hoy que la Agencia Europea de Medicamentos (EMA) ha aceptado revisar su solicitud de ampliar el uso de ...
GSK’s share price looks a steal to me anywhere below £43.29, and here’s why
GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...
ConSalud.es1d
GSK se dispara un 14,55% en el primer trimestre ante sus avances clínicos y regulatorios
La farmacéutica GSK tocó su máximo trimestral en marzo tras la publicación de datos clínicos, nuevos acuerdos y el respaldo ...
pharmaphorum1d
GSK says Nucala hits the target in new COPD trial
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
pharmaphorum5d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
Reuters2d
Future of Health
2025 Healthcare & Pharmaceuticalscategory European regulators to review GSK's asthma drug Nucala to treat COPD March 24, 2025 Healthcare & Pharmaceuticalscategory Brazil's Hypera to launch an ...
DIARIO MEDICO.COM3d
Nuevos respaldos para la británica GSK en ITUs y EPOC
La FDA autoriza el antibacteriano gepotidacina, primero de clase y primero frente a ITUs en 30 años, mientras que la EMA acepta revisar el uso de mepolizumab para añadirle la EPOC. Los compuestos ...